Clinical Trials on Reduction of Opioid Consumption and Pain Management through Full-Spectrum Hemp CBD

Image result for Clinical Trials on Reduction of Opioid Consumption and Pain Management through Full-Spectrum Hemp CBD


On November 14, Ecofibre Limited announced that they had published the outcomes of the 8-week study on CBD (cannabidiol), which is extracted from hemp in the Journal, Postgraduate Medical and Hospital Practice.

The Chief Science Officer of Ecofibre Ananda Health business in America, Dr. Alex Capana, said that 97 patients participated in the study, all the patients had been using opioids for more than a year to treat chronic pain. Besides, some had been consuming opioids for several decades.

Among all the patients, 94 of them added full-spectrum hemp CBD products (softgels) to their treatment program, and after the eight weeks 53% of the patients showed a reduction in opioid usage while 94% revealed an improvement in the quality of life measures such as better sleep, uplifted mood, and minimal or no pain.

The researchers used the Pittsburgh Sleep Quality Index and Pain Intensity and Interference Scale to statistically measure sleep quality and pain intensity, which showed a significant improvement.

The Ecofibre LTD Full-Spectrum softgels contains 15.7 mg of CBD, 0.5 mg of THC, 0.3 mg of CBDV, 0.9 of CBDA, and>1% of botanical terpene blend. The components of the softgels are safe and tolerable.

Not considering the survey, the study on the use of Hemp-Derived CBD in the reduction of opioid consumption and management of chronic pain has been the most significant in the marijuana industry, added Dr. Capano.

He further said that it is the first study to identify key data points on CBD and opioid reduction, such as doses of hemp extract, methods of consumption or use, and specific marijuana compounds. The majority of the patients involved in the study used lower doses of CBD, i.e., 30mg per day, while other studies focusing on CBD used ten or twenty times more. Patients who used lower doses reported minimal side effects and enhanced results.

Eric Wang, the managing director of Ecofibre Limited, noted that the study is still ongoing, and its primary purpose is to help people understand how CBD improves the quality of life. He added that the clinical trial is a stepping stone, and its results help advance people’s knowledge of CBD benefits.

Wang further said that the company’s goal is to add on the existing data to help educate regulators, doctors, pharmacists, and consumers.

The researchers were careful in patient recruitment and limitations for the clinical trials. The clinical was conducted in Kentucky at the Murphy Pain Center, where patients with a history of substance use disorder; a history of a non-fatal; psychotic disorder; an abnormal drug screen in the past year; epileptic episodes with the past year; cardiac arrest; renal; or if they are allergic to marijuana-based products.

Despite the study being the largest, it should consider the limitations such as a short trial period, placebo-controlled design, absence of participant’s control, a rather small sample size.

Three of the 97 participants opted out of the study midway. Another two experienced drowsiness as a side effect after consuming 15mg of CBD, and this was mitigated by lowering the dosage. Another patient said that her heartbeat increased significantly after using 15mg twice a day; the side effects were offset with a single dose of 30mg of CBD, which saw them to the end of the clinical trials. During the clinical trials, the participants did not report any severe reactions.

Out of the three who dropped out of the trials, one of them cited the high cost of the products should the therapy prove to be successful. Some of the other participants expressed the same concern. The patients further said that unless the products are issued under the insurance or sold at discounted prices through medical programs or institutions, accessing the CBD products will remain a challenge for those who are not financially stable.

Ecofibre Limited supplies hemp to the United States and Australian markets. The full-spectrum hemp extracts grown in Kentucky are used in the production of nutraceutical products for people and pet consumption. It is also used to make topical creams and salves in America. In Australia is used in the production of wellness products such as protein powders, or de-hulled hemp seed and oil through Ananda Food.

Ecofibre has partnered with Thomas Jefferson University to develop hemp-based fabrics and composite materials in the U.S.


Medcare 2023 event

Terms and Conditions for Entry into Medcare Farms Puff Party(Required)
| Age Requirement: You confirm that you are 21 years of age or older at the time of entering the Event. Valid government-issued photo identification must be presented upon request. | Compliance with Laws: You agree to comply with all federal, state, and local laws and regulations, including those pertaining to the use, possession, and distribution of any substances allowed or provided at the Event. | Liability Waiver: You acknowledge that participation in the Event is at your own risk. Medcare Farms, its affiliates, sponsors, representatives, and employees are not liable for any personal injury, loss, damages, or expenses incurred by you or any person accompanying you to the Event. | No Resale or Transfer: Your entry to the Event is personal to you; tickets or invitations cannot be sold, transferred, or exchanged for any compensation without the express permission of Medcare Farms. | Conduct: You agree to conduct yourself in a manner that is respectful and safe. Medcare Farms reserves the right to remove any participant from the Event for behavior deemed inappropriate, disruptive, or dangerous, without refund or compensation. | Use of Likeness: You grant Medcare Farms and its affiliates the right to use your likeness, image, and voice in photographs, videos, or other digital media taken at the Event, in any and all of its publications, including web-based publications, without payment or other consideration. | Privacy: Personal information collected during the survey and registration process will be used in accordance with Medcare Farms’ Privacy Policy. This information will be used for event management and, unless you opt-out, for informing you of future events and promotions. | Indemnification: You agree to indemnify and hold harmless Medcare Farms and its affiliates, officers, employees, and agents from and against any claims, liabilities, damages, losses, and expenses, including without limitation, reasonable attorney fees and costs, arising out of or in any way connected with your participation in the Event. | Acceptance of Risk: You acknowledge that there are inherent risks involved in attending the Event and that you voluntarily assume those risks. | Severability: If any term or provision of these Terms and Conditions is found to be invalid, illegal, or unenforceable, the remainder of the Terms and Conditions will remain in full force and effect. | Governing Law: These Terms and Conditions shall be governed by and construed in accordance with the laws of the state in which the Event is held, without giving effect to any principles of conflicts of law. | By checking this box, I confirm that I have read, understood, and agree to be bound by these Terms and Conditions.

Related Articles

Puff Party 2023

Medcare Farm’s Puff Party 2023 Welcome to Medcare Farms’ 2023 Puff Party, Complete our brief entry form to enjoy live

Read More »
Med CareLogo large

Are you over 21 years old?

Call Now Button